The Kestrel trial is a tree-arm study in HNSCC platinum-sensitive patients that evaluates the association between Tremelimumab (anti-CTLA4) and Durvalumab (anti-PD-L1) vs. Durvalumab alone vs. EXTREME protocol. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.